Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR440340 (Itepekimab) in Moderate-to-Severe COPD
NCT03546907Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2018
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Placebo with Itepekimab (2 arms). Primary endpoint: Annualized Rate of Moderate to Severe Acute Exacerbation of COPD at 52 weeks. Started Jul 2018; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03546907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546907.